Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses.

CONCLUSIONS: Exposure-response evaluations showed that both monthly (225 mg) and quarterly (675 mg) fremanezumab dosing regimens were appropriate in achieving clinical benefit in adult patients with EM or CM.
PMID: 32445498 [PubMed - as supplied by publisher]

Source: Headache - May 22, 2020 Category: Neurology Authors: Fiedler-Kelly J, Passarell J, Ludwig E, Levi M, Cohen-Barak O Tags: Headache Source Type: research